» Articles » PMID: 33860674

Contrast Enhanced Ultrasound Quantitative Parameters for Assessing Neoadjuvant Chemotherapy Response in Patients with Locally Advanced Breast Cancer

Overview
Journal Br J Radiol
Specialty Radiology
Date 2021 Apr 16
PMID 33860674
Citations 4
Authors
Affiliations
Soon will be listed here.
Abstract

Objectives: To evaluate the role of contrast-enhanced ultrasound (CEUS) quantitative parameters in predicting neoadjuvant chemotherapy (NACT) response in patients with locally advanced breast cancer (LABC).

Methods: 30 patients with histologically proven LABC scheduled for NACT were recruited. CEUS was performed using a contrast bolus of 4.8 ml and time intensity curves (TICs) were obtained by contrast dynamics software. CEUS quantitative parameters assessed were peak enhancement (PE), time-to-peak (TTP), area under the curve (AUC) and mean transit time (MTT). The parameters were documented on four consecutive instances: before NACT and 3 weeks after each of the three cycles. The gold-standard was pathological response using Miller Payne Score obtained pre NACT and post-surgery.

Results: A decrease in mean values of PE and an increase in mean values of TTP and MTT was observed with each cycle of NACT among responders. Post each cycle of NACT (compared with baseline pre-NACT), there was a statistically significant difference in % change of mean values of PE, TTP and MTT between good responders and poor responders (-value < 0.05). The diagnostic accuracy of TTP post-third cycle was 87.2% ( = 0.03), and MTT post--second and third cycle was 76.7% ( = 0.004) and 86.7% ( = 0.006) respectively.

Conclusion: In responders, a decrease in the tumor vascularity was reflected in the CEUS quantitative parameters as a reduction in PE, and a prolongation in TTP, MTT.

Advances In Knowledge: Prediction of NACT response by CEUS has the potential to serve as a diagnostic modality for modification of chemotherapy regimens during ongoing NACT among patients with LABC, thus affecting patient prognosis.

Citing Articles

A Comprehensive and Repeatable Contrast-Enhanced Ultrasound Quantification Approach for Clinical Evaluations of Tumor Blood Flow.

Krolak C, Wei A, Shumaker M, Dighe M, Averkiou M Invest Radiol. 2024; 60(4):281-290.

PMID: 39418656 PMC: 11888899. DOI: 10.1097/RLI.0000000000001127.


Clinical value of ultrasound parameters PI, TTP, and MTT in assessing cervical lymph node metastasis of papillary thyroid carcinoma.

Kong Q, Yu Y, Qian Q, Sun H Am J Transl Res. 2024; 16(3):809-816.

PMID: 38586094 PMC: 10994806. DOI: 10.62347/QWDR4613.


Multiparametric Contrast-Enhanced Ultrasound in Early Prediction of Response to Neoadjuvant Chemotherapy and Recurrence-Free Survival in Breast Cancer.

Wan C, Zhou L, Li H, Wang L, Li F, Yin W Diagnostics (Basel). 2023; 13(14).

PMID: 37510121 PMC: 10378059. DOI: 10.3390/diagnostics13142378.


Association between vascular ultrasound features and DNA sequencing in breast cancer: a preliminary study.

Han M, Park A, Seo B, Bae M, Kim J, Son G Discov Oncol. 2023; 14(1):52.

PMID: 37120792 PMC: 10149538. DOI: 10.1007/s12672-023-00657-8.


Prediction of Pathological Grades of Pancreatic Neuroendocrine Tumors Based on Dynamic Contrast-Enhanced Ultrasound Quantitative Analysis.

Yang D, Cheng J, Tian X, Zhang Q, Yu L, Qiu Y Diagnostics (Basel). 2023; 13(2).

PMID: 36673048 PMC: 9858178. DOI: 10.3390/diagnostics13020238.

References
1.
Chagpar A, Middleton L, Sahin A, Dempsey P, Buzdar A, Mirza A . Accuracy of physical examination, ultrasonography, and mammography in predicting residual pathologic tumor size in patients treated with neoadjuvant chemotherapy. Ann Surg. 2006; 243(2):257-64. PMC: 1448900. DOI: 10.1097/01.sla.0000197714.14318.6f. View

2.
Kim J, Kim J, Hwangbo L, Suh H, Kim S, Choo K . Kinetic Heterogeneity of Breast Cancer Determined Using Computer-aided Diagnosis of Preoperative MRI Scans: Relationship to Distant Metastasis-Free Survival. Radiology. 2020; 295(3):517-526. DOI: 10.1148/radiol.2020192039. View

3.
Saracco A, Szabo B, Tanczos E, Bergh J, Hatschek T . Contrast-enhanced ultrasound (CEUS) in assessing early response among patients with invasive breast cancer undergoing neoadjuvant chemotherapy. Acta Radiol. 2016; 58(4):394-402. DOI: 10.1177/0284185116658322. View

4.
Dong T . Early Response Assessed by Contrast-Enhanced Ultrasound in Breast Cancer Patients Undergoing Neoadjuvant Chemotherapy. Ultrasound Q. 2018; 34(2):84-87. DOI: 10.1097/RUQ.0000000000000333. View

5.
Cosgrove D . Ultrasound contrast agents: an overview. Eur J Radiol. 2006; 60(3):324-30. DOI: 10.1016/j.ejrad.2006.06.022. View